Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Genetics
|
December 15, 2015
Exploiting Linkage Disequilibrium for Ultrahigh-Dimensional Genome-Wide Data with an Integrated Statistical Approach
Michelle Carlsen, Guifang Fu, Shaun Bushman, et al.
Translational Lung Cancer Research
|
September 11, 2023
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with <i>EGFR</i>-activating mutations (RELAY phase 3 randomized study)
Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Mutation-Specific Response to Ramucirumab in <i>EGFR-</i>Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)
Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
JTO Clinical and Research Reports
|
February 2, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, <i>EGFR</i>-Mutated, Metastatic NSCLC: Outcomes by <i>EGFR</i> Exon 19 Deletion Variants
Kazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, et al.
Investigational New Drugs
|
February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
Afshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
JTO Clinical and Research Reports
|
November 24, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC
Makoto Nishio, Takashi Seto, Martin Reck, et al.
JTO Clinical and Research Reports
|
June 3, 2025
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC: RELAY Japanese Subset
Makoto Nishio, Takashi Seto, Martin Reck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
Antoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Karen A Autio, Christopher A Klebanoff, David Schaer, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Genetics
|
December 15, 2015
Exploiting Linkage Disequilibrium for Ultrahigh-Dimensional Genome-Wide Data with an Integrated Statistical Approach
Michelle Carlsen, Guifang Fu, Shaun Bushman, et al.
Translational Lung Cancer Research
|
September 11, 2023
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with <i>EGFR</i>-activating mutations (RELAY phase 3 randomized study)
Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Mutation-Specific Response to Ramucirumab in <i>EGFR-</i>Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)
Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
JTO Clinical and Research Reports
|
February 2, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, <i>EGFR</i>-Mutated, Metastatic NSCLC: Outcomes by <i>EGFR</i> Exon 19 Deletion Variants
Kazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, et al.
Investigational New Drugs
|
February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
Afshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
JTO Clinical and Research Reports
|
November 24, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC
Makoto Nishio, Takashi Seto, Martin Reck, et al.
JTO Clinical and Research Reports
|
June 3, 2025
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC: RELAY Japanese Subset
Makoto Nishio, Takashi Seto, Martin Reck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
Antoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Karen A Autio, Christopher A Klebanoff, David Schaer, et al.
Page
of 1